Search bioRxiv⌕ Search

Biology subjects

Vincent, B.

Publications and source records attributed to Vincent, B..

11 recordsLinked to original sources

Peptide:MHC Binding Stability Prediction Using Protein Language Models

AO_SCPLOWBSTRACTC_SCPLOWPeptide:MHC class I (pMHC-I) binding stability governs the persistence of antigenic complexes at the cell surface and plays a key role in facilitating downstream immunological signals such as antigen presentation, T-cell activation, and immunodominance. However, methods for in silico stability prediction remain underexplored relative to binding affinity prediction, in part because available half-life datasets are sparse and expensive to collect. Here, we perform a systematic reassessment of pMHC-I stability prediction using controlled, similarity-aware data splits and apply a recently introduced supervised transfer-learning strategy to MINT, an interaction-aware protein language model, pre-trained on binding affinity and fine-tuned for quantitative half-life prediction. We show that MINT improves stability prediction over standard ESM-2 representations and existing predictors, and that assay-conditioned recalibration corrects systematic shifts across experimental measurement modalities. Across eluted ligand, immunogenicity, and personalized neoantigen prioritization benchmarks, predicted stability provides signal beyond binding affinity, enriching for naturally presented and immunogenic peptides within affinity-filtered candidate sets. These results establish pMHC-I half-life as an orthogonal and transferable biophysical signal connecting peptide binding, surface presentation, and T-cell recognition, and provide a leakage-aware, assay-aware framework for future antigen-presentation modeling.

bioinformatics↗

Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy

Immune checkpoint inhibition (ICI) is clinically active against multiple cancers, including urothelial cancer at the non-muscle invasive, muscle-invasive, and metastatic stages. Despite this, large numbers of patients experience disease progression and relapse after treatment with ICI-containing regimens. Tumor antigen-specific T cells are critical to ICI response, however few studies have evaluated the breadth and magnitude of tumor antigen-specific T cell responses with ICI therapy. In this study, we mapped the tumor antigen immunodominance hierarchy in the BBN963 model of murine basal-like bladder cancer for endogenous tumor neoantigens expressed physiologically. We used a high-throughput matrixed ELISpot assay to detect CD8+ T cell responses to predicted BBN963 tumor antigens derived from multiple mutational genomic sources. We found CD8+ T cell responses were directed against a subset of tumor antigens forming a stable and reproducible immunodominance hierarchy across individual mice. Treatment with anti-PD-1 or anti-CTLA-4 did not substantially reshape this hierarchy or broadly shift dominant responses to previously defined subdominant epitopes. Predicted peptide MHC binding stability and affinity was associated with antigen immunogenicity. Cancer-testis antigens, endogenous retroviral antigens, and SNV-derived tumor antigens that were immunogenic were found across tumor subclones. By diversifying the immunogenic antigen repertoire beyond SNVs, we achieved nearly 100% tumor subclone coverage, suggesting that broader antigen selection could help immunotherapy target more tumor subclones. In conclusion, this study supports the stability of the immunodominance hierarchy under ICI therapy and a role for broadening antigen discovery to multiple expressional sources in immunotherapy design.

cancer biology↗

TCR-TRANSLATE: Conditional Generation of Real Antigen Specific T-cell Receptor Sequences

The paradoxical nature of T-cell receptor (TCR) specificity, which requires both precise recognition and adequate coverage of antigenic peptide-MHCs (pMHCs), poses a fundamental challenge in immunology. Efforts at modeling this complex many-to-many mapping have been greatly impeded by a severe lack of experimental data. To address this, we present TCR-TRANSLATE, a novel framework that adapts low-resource machine translation techniques to the TCR:pMHC specificity domain. Here, we explore sequence-to-sequence (seq2seq) modeling with various training strategies, including semi-synthetic data augmentation and multi-task objectives to generate antigen specific TCR sequences for a given target of interest. We benchmark twelve model variants derived from the BART and T5 model architectures on a target-rich validation set of well-studied pMHCs, finding an optimal model, TCRT5, that generated validated antigen-specific CDR3{beta} sequences for previously unseen antigens. While current limitations include a narrow validation set and a focus on the CDR3{beta} loop, our approach demonstrates the potential of seq2seq models in rapidly generating antigen-specific TCR repertoires, offering a promising avenue for increasing throughput in precision immunotherapies. Our findings highlight both the capabilities and limitations of sequence-based conditional TCR design, emphasizing the need for experimental validation to bridge the gaps between predictions, metrics, and functional capacity.

synthetic biology↗

Preliminary attempt to inhibit proliferation of NUT carcinoma cell lines using antisense oligonucleotides targeting NUTM1

NUT carcinoma is an aggressive cancer driven by NUTM1 fusion proteins. This study evaluated antisense oligonucleotides (ASOs) targeting NUTM1 as a potential therapeutic approach. Three ASOs targeting NUTM1 and scrambled controls were tested at 10-50 nM doses in three NUT carcinoma cell lines (TC-797, 10-15, 14169) and one control line (293T). ASOs were delivered both gymnotically and using a transfection reagent. Cell viability was assessed at 48 and 72 hours using a luminescence-based assay. No ASOs showed selective inhibition of NUT carcinoma cell viability compared to controls across all conditions tested. Thus, this pilot study did not identify ASOs with activity against NUT carcinoma cells. However, it did establish preliminary protocols and generated data to inform future ASO optimization efforts targeting NUTM1 in NUT carcinoma. Further refinement of ASO design and delivery methods is needed to identify therapeutic candidates. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=135 SRC="FIGDIR/small/605673v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@de8a08org.highwire.dtl.DTLVardef@383db9org.highwire.dtl.DTLVardef@5c4500org.highwire.dtl.DTLVardef@1b6325f_HPS_FORMAT_FIGEXP M_FIG C_FIG HypothesisThis experiment was performed as a pilot experiment to generate data to inform future work, which should include formal hypothesis testing with a reduced number of conditions. The hypothesis of this pilot experiment was that one or more of the non-scrambled antisense oligonucleotides (ASOs) targeting NUTM1 will selectively decrease proliferation and/or viability of NUT carcinoma cells, indicated by a reduction in luminescence (as compared to treated non-NUT carcinoma and untreated NUT carcinoma control cells) using the CellTiter-Glo Luminescent Cell Viability Assay.

cancer biology↗

Comparing Long Read Fusion Callers using Simulated Read Data

The advent of single-molecule third generation sequencing technologies provide new possibilities for the detection of fusion transcripts in sequencing data. Here, we test three long-read fusions detection tools on simulated data, compare various tooling parameters and compare the performance between long-read and short-read fusion detection tools. We also use our fusion transcript detection pipeline to describe fusions transcripts detected in U87 and U937 glioblastoma cell lines. We find that LongGF is the most capable of the long-read fusion detection tools at identifying the most simulated fusion transcripts. While the short read fusion transcript detection tool, Arriba, had similar recall to some of the long-read tools, its precision was found to be much lower. Several fusions with ample evidence were found in U87 and U937 cell lines.

bioinformatics↗

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

T cell responses to minor histocompatibility antigens (mHAs) mediate graft versus leukemia (GvL) effects and graft versus host disease (GvHD) in allogeneic hematopoietic cell transplant (alloHCT). Therapies that boost T cell responses improve the efficacy of alloHCT; however, these have been limited by concurrent increases in the incidence and severity of GvHD. mHAs with expression restricted to hematopoietic tissue (GvL mHAs) are attractive targets for driving GvL without causing GvHD. Prior work to identify mHAs has focused on a small set of mHAs or population-level SNP association studies. We report here the discovery of a large set of novel GvL mHAs based on predicted peptide immunogenicity, restriction of expression to hematopoietic tissue or GvHD target organs, and degree of sharing among donor-recipient pairs (DRPs) in the DISCOVeRY-BMT dataset of 3231 alloHCT DRPs. The total number of predicted mHAs and count within each class of predicted mHAs significantly differed by recipient genomic ancestry group, with European American>Hispanic>African American for each. The number of mHAs also differed markedly by HLA allele, even among alleles of the same gene. From the pool of predicted mHAs, we identified the smallest sets of GvL mHAs needed to cover 100% of DRPs with a given HLA allele. We then used mass spectrometry to search for high population frequency mHAs for three common HLA alleles. We validated a total of 24 novel predicted GvL mHAs that cumulatively are found within 98.8%, 60.7%, and 78.9% of DRPs within DISCOVeRY-BMT that express HLA-A*02:01, HLA-B*35:01, and HLA-C*07:02 respectively. We also confirmed in vivo immunogenicity of one example novel mHA via coculture of healthy human CD8 T cells with mHA-pulsed dendritic cells. This work demonstrates that identification of shared mHAs is a feasible and promising technique for expanding mHA-targeting immunotherapeutics to larger numbers of patients.

cancer biology↗

ADAM10 pharmacological inhibition modifies the expression of components of the dopaminergic system

Dopamine is a primary neurotransmitter associated with memory formation, emotional control, reward processing and other higher order mental functions. Altered dopamine signaling is implied in several neuropsychiatric, neurodevelopmental and neurodegenerative disorders including Alzheimers disease. Age-related memory decline often presents itself with spectrum of overtly behavioral responses in patients diagnosed with Alzheimers disease, thus suggesting that an alteration of dopaminergic transmission could account for the psychotic symptoms observed along the pathology. Since less sAPP production due to reduced -secretase activity is a direct contributor of compromised neuroprotection and can impart higher vulnerability to cellular insults, we explored the impact of specific inhibition of ADAM10, the main neuronal -secretase, on dopamine system components in cultured human SH-SY5Y neuroblastoma cells. We found that dopamine receptor D4 protein levels were dose-dependently down regulated by GI254023X, but not by the ADAM17-specific inhibitor TAPI-0. We then established that GI254023X operates at a transcriptional levels. Furthermore, we showed that GI254023X treatment also significantly increased the levels of active PKA as well as the transcription of the dopamine-degrading enzymes catechol-O-methyltransferase, monoamine oxidase A and monoamine oxidase B. Altogether, our data propose that ADAM10 inhibition modulates the dopaminergic system to possibly trigger psychosis in Alzheimers disease.

neuroscience↗

LENS - Landscape of Effective Neoantigens Software

MotivationElimination of cancer cells by T cells is a critical mechanism of anti-tumor immunity and cancer immunotherapy response. T cells recognize cancer cells by engagement of T cell receptors with peptide epitopes presented by major histocompatibility complex (MHC) molecules on the cancer cell surface. Peptide epitopes can be derived from antigen proteins coded for by multiple genomic sources. Bioinformatics tools used to identify tumor-specific epitopes via analysis of DNA and RNA sequencing data have largely focused on epitopes derived from somatic variants, though a smaller number have evaluated potential antigens from other genomic sources. ResultsWe report here an open-source workflow utilizing the Nextflow DSL2 workflow manager, Landscape of Effective Neoantigen Software (LENS), which predicts tumor-specific and tumor-associated antigens from single nucleotide variants, insertions and deletions, fusion events, splice variants, cancer testis antigens, overexpressed self-antigens, viruses, and endogenous retroviruses. The primary advantage of LENS is that it expands the breadth of genomic sources of discoverable tumor antigens using genomics data. Other advantages include modularity, extensibility, ease of use, and harmonization of relative expression level and immunogenicity prediction across multiple genomic sources. We present an analysis of 115 acute myeloid leukemia (AML) samples to demonstrate the utility of LENS. We expect LENS will be a valuable platform and resource for T cell epitope discovery bioinformatics, especially in cancers with few somatic variants where tumor-specific epitopes from alternative genomic sources are an elevated priority. AvailabilityMore information about LENS, including workflow documentation and instructions, can be found at https://gitlab.com/landscape-of-effective-neoantigens-software Contactsteven_vensko@med.unc.edu, benjamin_vincent@med.unc.edu Supplementary informationSupplementary data are available at Bioinformatics online.

cancer biology↗

Longitudinally modeling anti-neoantigen immunity under paradigms of immunodominance

Predator-prey theory is commonly used to approximately describe tumor growth in the presence of selective pressure from the adaptive immune system. These interactions are mediated by the tumor immunopeptidome (what the tumor "shows" the body) and the T-cell receptor (TCR) repertoire (how well the body "sees" cancer cells). Importantly, both tumor and T cell populations are dynamic and in competition with each other and their fraternal lineages. In particular, the immunopeptidome comprises neoantigens which can be gained and lost throughout tumorigenesis and treatment. Heterogeneity in the immunopeptidome is predictive of poorer survival and response to T-cell dependent immunotherapy in some tumor types, suggesting the TCR repertoire is unable to support a fully polyclonal response against every neoantigen. Whether between-lineage competition among T cells plays a role, and in what contexts, is unknown; moreover, longitudinal TCR profiling studies are expensive and logistically complex to conduct. In silico models may offer an inexpensive way to interrogate these phenomena ex ante and deepen our understanding of the tumor-immune axis. Here, we construct and calibrate a predator-prey-like model to preclinical and clinical data to describe tumor growth and immunopeptidome diversification. Simultaneously, we model the expansion of neoantigen-specific T cell lineages and their consumption of both lineage-specific and shared, lineage-agnostic resources. This predator-prey-like framework accurately described clinically observed immunopeptidomes as well as correlates and consequences of response to immunotherapy, including immunoediting. The model was also suitable for exploring treatment of tumors with varying growth and mutation rates.

cancer biology↗

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth

The threshold for immunogenic clonal fraction in a heterogeneous solid tumor required to induce effective bystander killing of non-immunogenic subclones is unknown. Pancreatic cancer poses crucial challenges for immune therapeutic interventions due to low mutational burden and consequent lack of neoantigens. Here, we designed a model to incorporate artificial neoantigens into genes of interest in cancer cells and to test the potential of said antigens to actuate bystander killing. By precisely controlling the abundance of a neoantigen in the tumor, we studied the impact of neoantigen frequency on immune response and immune escape. Our results showed that a single, strong, widely expressed neoantigen could lead to a robust antitumor response when at least 80% of cancer cells express the neoantigen. Further, immunological assays revealed induction of T-cell responses against a non-target self-antigen on KRAS oncoprotein, when we inoculated animals with a high frequency of tumor cells expressing a test neoantigen. Using nanoparticle-based gene therapy, we successfully altered the tumor microenvironment by perturbing interleukin-12 and interleukin-10 gene expression. The subsequent remodeling of the microenvironment reduced the threshold of neoantigen frequency at which bioluminescent signal intensity for tumor burden decreased 1.5-logfold, marking a robust tumor growth inhibition, from 83% to as low as 29%. Our results thus suggest that bystander killing is rather inefficient in immunologically cold tumors like pancreatic cancer and requires an extremely high abundance of neoantigens. However, the bystander killing mediated antitumor response can be rescued, when supported by adjuvant immune therapy.

cancer biology↗

STIG: Generation and simulated sequencing of synthetic T cell receptor repertoires

T cell receptor repertoire inference from DNA and RNA sequencing experiments is frequently performed to characterize host immune responses to disease states. Existing tools for repertoire inference have been compared across publicly available biological datasets or unpublished simulated sequencing data. Evaluation and comparison of these tools is challenging without common data sets created from a known repertoire with well-defined biological and sequencing characteristics. Here we introduce STIG, a tool to create simulated T cell receptor sequencing data from a customizable virtual T cell repertoire, with clear attribution of individual reads back to locations within their respective T-cell receptor clonotypes. STIG allows for robust performance evaluation of T cell repertoire inference and downstream analysis methods. STIG is implemented in Python 3 and is freely available for download at https://github.com/Benjamin-Vincent-Lab/stig Author summaryAs part of the acquired immune system, T cells are integral in the host response to microbes, tumors and autoimmune disease. These cells each have a semi-unique T cell receptor that serves to bind a set of antigens that will in turn stimulate that cell to perform its particular pro- (or anti) inflammatory role. This receptor is the product of DNA rearrangement of germline gene segments, similar to B cell receptor loci rearrangement, which provides a wide variety of potential T cell receptors to respond to antigens. At the site of an immune reaction, T cells can increase their number through clonal expansion and methods have been developed to analyze bulk genetic sequencing data to infer the individual receptors and the relative size of their clonal subpopulations present within a sample. To date, these methods and tools have been tested and compared using either biological samples (where the true quantitiy and types of T cells is unknown) or unshared synthetic datasets. In this paper I describe a new tool to generate biologically-inspired T-cell repertoires in-silico and generate simulated sequencing data from them.

genomics↗